Breast Implants
Breast implants are placed either for cosmetic augmentation or to reconstruct the breast after cancer surgery, and millions of women have them. They are not permanent devices: they have a finite lifespan, and most women will need further surgery at some point. From an imaging perspective they raise two distinct questions—whether the implant itself is intact and behaving normally, and how its presence affects the detection of breast cancer in the surrounding tissue. Both are answerable, and understanding what imaging can and cannot show with implants in place is useful for any woman who has them, particularly when attending screening.
What is it?
A breast implant is a device placed in the breast to increase its size or to rebuild it after mastectomy. All implants consist of a silicone outer shell filled with either silicone gel or sterile saline.
Silicone gel implants are the most commonly used. Modern versions contain a cohesive gel that holds its shape rather than flowing freely, which means that if the shell tears, the gel largely stays within the capsule rather than dispersing. This cohesiveness is the reason silicone rupture frequently produces no visible or palpable change at all—a situation described as silent rupture, and the reason imaging rather than examination is required to detect it.
Saline implants are filled with sterile salt water. If the shell ruptures, the saline leaks out and is harmlessly absorbed by the body, and the implant visibly deflates over hours to days. Rupture is therefore obvious and requires no imaging to diagnose.
Implants may be placed in front of the chest muscle, behind it, or in a partially submuscular position. Placement behind the muscle generally allows better imaging of the breast tissue and is associated with lower rates of capsular contracture, though it has other trade-offs.
The surface of the implant may be smooth or textured. Textured surfaces were developed to reduce capsular contracture and to hold anatomically shaped implants in position. They are also the surface associated with BIA-ALCL, and several textured implant types have been withdrawn from the market in multiple countries as a result.
One concept is central to understanding implant behaviour. After any implant is placed, the body forms a layer of fibrous tissue around it—the capsule. This is a normal and expected response, occurring with any foreign material, and it is not a complication in itself. The capsule holds the implant in position. Problems arise when this capsule thickens and contracts.
Capsular contracture is the most common complication requiring further surgery. The capsule tightens progressively, squeezing the implant, which makes the breast feel firm, distorts its shape by pushing it higher and making it rounder, and may cause pain. It is graded from barely detectable firmness through to a hard, distorted, painful breast. The cause is not fully established, though low-grade bacterial contamination forming a biofilm on the implant surface, bleeding around the implant, and radiotherapy are all implicated. Rates are higher after reconstruction than after cosmetic augmentation, and markedly higher where radiotherapy has been given.
Rupture is the other principal mechanical problem. Implant shells weaken over time, and rupture rates rise with implant age. With silicone implants, the gel may remain within the capsule, described as intracapsular rupture, or escape beyond it, described as extracapsular rupture, with the latter being less common and more likely to cause visible change or lumps in surrounding tissue. Silicone that has migrated can form firm nodules known as silicone granulomas, sometimes in the armpit lymph nodes.
Implants are not lifetime devices, and this deserves plain statement because it is frequently not fully appreciated at the time of surgery. A substantial proportion of women require further surgery within a decade, whether for contracture, rupture, change in breast shape with age or weight change, or dissatisfaction with appearance. Anyone considering implants should understand that further operations are likely rather than possible.
BIA-ALCL—breast implant-associated anaplastic large cell lymphoma—requires accurate description because it causes considerable anxiety. It is a rare lymphoma that arises in the fluid and capsule around an implant rather than in the breast tissue itself, and it is not breast cancer. It is associated almost exclusively with textured implants, and risk varies substantially by the degree of texturing. It typically presents years after implantation, most often as persistent swelling of one breast caused by fluid collecting around the implant, and less often as a lump. Diagnosis is made by sampling that fluid. When detected early and treated by complete removal of the implant and capsule, outcomes are excellent and the condition is curable in the great majority. Several textured implant types have been withdrawn, and current guidance in most countries does not recommend removing implants in women without symptoms, but does recommend prompt assessment of new breast swelling.
Breast implant illness is a term used by women who report a cluster of systemic symptoms—fatigue, joint and muscle pain, cognitive difficulty, rashes, and others—which they attribute to their implants. This deserves careful and respectful handling. Large epidemiological studies have not established a causal link between implants and defined autoimmune or connective tissue diseases. At the same time, substantial numbers of women report these symptoms, and a proportion describe improvement after implant removal. Research is ongoing, the mechanisms are not understood, and the honest position is that the symptoms are real and experienced, while the causal relationship remains unproven. Women raising these concerns deserve to be taken seriously and assessed properly rather than dismissed, and explantation is a legitimate choice that some surgeons offer for this reason.
Symptoms are absent in most women with implants for most of the time.
Where they occur, progressive firmness and change in shape suggest capsular contracture. A sudden decrease in size indicates saline rupture. Silicone rupture frequently produces nothing at all, though it may cause a change in shape, firmness, new lumps, or discomfort.
Persistent swelling of one breast developing years after surgery is the presentation that most warrants prompt attention, given the association with BIA-ALCL.
Pain, rippling visible at the implant edge, asymmetry, and palpable folds are common and usually mechanical rather than sinister.
Redness, warmth, swelling, and fever suggest infection, which is most common in the early period after surgery but can occur later.
The imaging considerations are where this subject intersects most directly with breast care, and they fall into two separate questions.
The first is whether the implant is intact. MRI is the most accurate test for silicone rupture and is the reference standard, identifying characteristic appearances including the linguine sign, where the collapsed shell is seen as wavy lines floating within the surrounding silicone. Ultrasound is widely available, inexpensive, and performs reasonably well in experienced hands, with a stepladder appearance being its equivalent sign, though it is less sensitive than MRI. Mammography detects extracapsular silicone but is poor at identifying intracapsular rupture.
The second question is whether cancer can still be detected, and this is the more important one for most women.
Implants are radio-opaque and obscure the breast tissue behind them on mammography. Specialised technique helps considerably: implant displacement views, sometimes called Eklund views, involve pushing the implant backward against the chest wall and pulling the breast tissue forward, allowing much more of it to be imaged. Additional standard views are taken alongside these. Even so, some tissue remains obscured, and sensitivity is modestly reduced compared with women without implants.
The practical implications are straightforward. Women with implants should continue to attend routine screening at the same intervals as anyone else—having implants is not a reason to stop. They should always inform the service in advance, so that appropriate technique is used and enough time is allocated. Where a finding needs further assessment, ultrasound and MRI are used as they would be otherwise, and both perform well in the presence of implants. Women who have had implants placed for reconstruction after mastectomy follow a different surveillance pathway determined by their cancer team.
A separate point concerns women who have had fat grafting or free silicone or other filler injections, rather than implants. Free injected material produces appearances on imaging that can be difficult to interpret and that may mimic or obscure disease, and this history should be disclosed when attending for imaging.
Important to Know
The most useful framing is that implants are durable medical devices requiring long-term awareness rather than ongoing anxiety. Most women have them for years without difficulty, and the issues that arise are generally manageable. Care involves plastic and breast surgeons, breast radiologists, and for women with reconstruction, the oncology team.
Several practical points deserve emphasis.
Implants do not last indefinitely. Planning on the basis that further surgery will probably be needed at some stage is realistic, and this should be understood before the first operation rather than discovered afterwards. Keeping the implant details—manufacturer, type, size, and date of surgery—is genuinely useful, since this information is needed if problems arise and is often difficult to retrieve years later. Many countries now maintain implant registries for this purpose.
Routine imaging surveillance of asymptomatic implants is handled differently in different countries. Regulatory guidance in the United States has recommended periodic MRI or ultrasound screening for silent rupture of silicone implants beginning several years after placement, while practice elsewhere, including the United Kingdom, has generally not recommended routine imaging in the absence of symptoms. This divergence reflects genuine uncertainty about whether detecting silent rupture earlier changes outcomes, and it is reasonable to ask what approach applies locally.
Capsular contracture is treated surgically once established. Non-surgical measures including massage and medication have been tried extensively and are largely ineffective for established contracture. Surgery involves removing or releasing the capsule, usually with implant exchange, and recurrence is possible.
A ruptured silicone implant is generally removed, but the urgency is low where there are no symptoms. The cohesive gel in modern implants does not disperse widely, and there is no evidence that a contained rupture causes systemic harm. The decision and its timing can be made without alarm.
Removal without replacement—explantation—is a legitimate choice and is increasingly requested. It can be performed with removal of the capsule where indicated. Women should understand that the breast appearance after removal differs from its appearance before implants were ever placed, since the tissue has been stretched and may have thinned, and discussing realistic expectations beforehand matters.
Any new, persistent swelling of one breast years after implant surgery should be assessed promptly, with fluid sampled and tested specifically for BIA-ALCL. This is the single most important symptom to recognise, and the message is to seek assessment rather than to worry pre-emptively, since the condition is rare and highly curable when caught early.
Screening attendance should continue unchanged. This is worth stating clearly, because some women assume implants make mammography impossible or pointless. They do not. Technique is adapted, sensitivity is modestly reduced, and the test remains worthwhile. Informing the service in advance is the practical step that matters.
Breast awareness remains important. Implants do not prevent breast cancer, and cancers occurring in women with implants are generally found at similar stages to those in women without. Any new lump, skin change, or nipple change should be reported in the usual way.
Breastfeeding is possible for most women with implants, particularly where the incision avoided the areola and where the nipple-areola complex and ducts were preserved. Some women experience reduced supply, and this is worth discussing before surgery for anyone planning future pregnancy.
For women with implant-based reconstruction after cancer, additional considerations apply. Radiotherapy substantially increases the risk of capsular contracture and implant failure, which influences whether implant-based or tissue-based reconstruction is chosen. Surveillance after reconstruction follows the oncology team’s protocol rather than routine screening.
Where systemic symptoms are attributed to implants, assessment should be thorough rather than dismissive, excluding other causes while taking the concern seriously. Explantation is offered by some surgeons in this situation, and while evidence for benefit is limited, the decision is a legitimate one for a woman to make with proper information.
Care involves plastic surgery, breast surgery, and breast radiology, with oncology for reconstruction patients. Imaging and clinical findings are interpreted alongside implant type, age, and surgical history, which makes retaining those records worthwhile.
Patient education plays an important role. Understanding that implants require future surgery, that silicone rupture is frequently silent and needs imaging to detect, that screening should continue with adapted technique, that persistent one-sided swelling warrants prompt assessment, and that systemic symptom concerns deserve proper evaluation all contribute to appropriate care.
Red flag symptoms include persistent swelling of one breast developing months or years after implant surgery, which requires prompt assessment for BIA-ALCL; a new lump in the breast or armpit; redness, warmth, swelling, and fever suggesting infection; sudden change in breast shape or size; a breast that has become progressively hard, distorted, or painful; skin changes including dimpling or tethering; nipple changes or discharge; and any new breast symptom, which should be assessed on its own merits rather than attributed to the implant. These warrant medical evaluation, urgently where infection or persistent swelling is present.